Gregory L. Verdine - 11 Aug 2025 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Reporting relationship: Director
Issuer ticker: WVE
Reported as of: 11 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Aug 2025, 20:00:06 UTC
Prior SEC filing: 13 Jun 2025
Next SEC filing: 26 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Gregory L. Verdine

Key filing fact

Gregory L. Verdine filed Form 4 for Wave Life Sciences Ltd. (WVE) on 13 Aug 2025.

Key facts

This page summarizes Gregory L. Verdine's Form 4 filing for Wave Life Sciences Ltd. (WVE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Aug 2025, 20:00.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001572315 Primary reporting owner

Verdine Gregory L.

Relationship: Director
Address: C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE
Signature: /s/ Gregory L. Verdine
Signature date: 13 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WVE transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +12,700
Change %: +4.5%
Price: $0.000000
Shares after: 295,217
Date: 11 Aug 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WVE transaction Derivative

Share Option (right to buy)

Award

Transaction value: $0
Shares: +76,200
Change %
Price: $0.000000
Shares after: 76,200
Date: 11 Aug 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 76,200
Exercise price: $8.10
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026.

Footnote F2

The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026.